Steris (NYSE: STE) reported Q3 EPS of $1.73, $0.21 better than the analyst estimate of $1.52. Revenue for the quarter came in at $808.9 million versus the consensus estimate of $792.98 million.

“We continue to be impressed by the resilience of our business and the good work by STERIS Associates,” said Walt Rosebrough, President and Chief Executive Officer of STERIS. “In our third quarter, Healthcare capital equipment orders continued their sequential improvement, resulting in near record backlog at the end of December. As anticipated, Life Sciences consumable Customers appear to have worked through inventory, resulting in a return to more normalized revenue growth rates, and AST continues its path of strong growth. We are well positioned to finish another record year in revenue and income during fiscal 2021 and look forward to welcoming Cantel Medical to the STERIS family in fiscal 2022.”

For earnings history and earnings-related data on Steris (STE) click here.